| Literature DB >> 33782306 |
Marcus Unterrainer, Simon Lindner1, Leonie Beyer1, Franz J Gildehaus1, Andrei Todica1, Lena M Mittlmeier1, Klaus Jurkschat2, Carmen Wängler3, Bjoern Wängler4, Ralf Schirrmacher5, Jörg C Tonn6, Nathalie L Albert1, Peter Bartenstein1, Harun Ilhan1.
Abstract
ABSTRACT: PET using 68Ga-labeled somatostatin receptor (SSTR) ligands adds significant information in meningioma patients. 18F-SiTATE is a novel, 18F-labeled SSTR-targeting peptide with remarkable imaging properties. Here, we present a 72-year-old woman with falx meningioma and transosseous extension. 18F-SiTATE PET/CT was performed 12 months after the previous 68Ga-DOTATOC PET/CT with comparable quantitative uptake and very good spatial resolution. So far, the widespread use of SSTR ligands for NET and meningioma imaging is hampered by cost-intensive 68Ge/68Ga generators, low activity amounts, lower spatial resolution, and short half-life. 18F-SiTATE might foster widespread use of SSTR ligands, overcoming the shortcomings of 68Ga-labeled ligands.Entities:
Year: 2021 PMID: 33782306 DOI: 10.1097/RLU.0000000000003607
Source DB: PubMed Journal: Clin Nucl Med ISSN: 0363-9762 Impact factor: 7.794